<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38069039</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>23</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Predictive Factors and <i>ACE-2</i> Gene Polymorphisms in Susceptibility to Long COVID-19 Syndrome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">16717</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms242316717</ELocationID><Abstract><AbstractText>Long COVID-19 syndrome is present in 5-10% of patients infected with SARS-CoV-2, and there is still little information on the predisposing factors that lead to its development. The purpose of the study was to evaluate the predictive factors in early symptoms, clinical features and the role of Angiotensin-Converting Enzyme-2 (<i>ACE-2</i>) c.513-1451G&gt;A (rs2106806) and c.15643279T&gt;C (rs6629110) polymorphisms in the susceptibility to developing Long COVID-19 syndrome subsequent to COVID-19 infectionA total of 29 patients who suffered COVID-19 were recruited in a descriptive longitudinal study of two groups: Long COVID-19 (n = 16) and non-Long COVID-19 (n = 13). Early symptoms and clinical features during COVID-19 were classified by a medical service. <i>ACE-2</i> polymorphisms were genotyped by using a Single Nucleotide Primer Extension (SNPE). Of the early symptoms, fatigue, myalgia and headache showed a high risk of increasing Long COVID-19 susceptibility. Clinical features such as emergency care, SARS-CoV-2 reinfection, previous diseases, respiratory disease and brain fog also had a high risk of increasing Long COVID-19 susceptibility. The A allele in the rs2106806 variant was associated with an odds ratio (OR) of 4.214 (95% CI 2.521-8.853; <i>p</i> &lt; 0.001), and the T allele in the rs6629110 variant was associated with an OR of 3.754 (95% CI 1.785-6.105; <i>p</i> = 0.002) of increasing Long COVID-19 susceptibility. This study shows the risk of <i>ACE-2</i> polymorphisms, different early symptoms and clinical features during SARS-CoV-2 infection in susceptibility to Long COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Varillas-Delgado</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5026-2701</Identifier><AffiliationInfo><Affiliation>Department of Exercise and Sport Science, Faculty of Health Sciences, Universidad Francisco de Vitoria, Pozuelo, 28223 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez-Antona</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9253-8884</Identifier><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, Universidad Rey Juan Carlos, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lizcano-Alvarez</LastName><ForeName>Angel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0022-9652</Identifier><AffiliationInfo><Affiliation>Department of Nursing and Stomatology, Faculty of Health Sciences, Universidad Rey Juan Carlos, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cano-de-la-Cuerda</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1118-4234</Identifier><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, Universidad Rey Juan Carlos, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molero-Sanchez</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, Universidad Rey Juan Carlos, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laguarta-Val</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8836-7135</Identifier><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, Universidad Rey Juan Carlos, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE-2 gene</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">early symptoms</Keyword><Keyword MajorTopicYN="N">polymorphisms</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38069039</ArticleId><ArticleId IdType="pmc">PMC10705995</ArticleId><ArticleId IdType="doi">10.3390/ijms242316717</ArticleId><ArticleId IdType="pii">ijms242316717</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yong S.J. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect. Dis. 2021;53:737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F., Perego E. How and why patients made Long COVID. Soc. Sci. Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of COVID-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett D.M., Skinner C.E. Year in Review: Long COVID and Pulmonary Rehabilitation. Respir. Care. 2023;68:846&#x2013;851. doi: 10.4187/respcare.10928.</Citation><ArticleIdList><ArticleId IdType="doi">10.4187/respcare.10928</ArticleId><ArticleId IdType="pmc">PMC10209004</ArticleId><ArticleId IdType="pubmed">37185117</ArticleId></ArticleIdList></Reference><Reference><Citation>Besnier F., B&#xe9;rub&#xe9; B., Malo J., Gagnon C., Gr&#xe9;goire C.A., Juneau M., Simard F., L&#x2019;Allier P., Nigam A., Igl&#xe9;sies-Grau J., et al. Cardiopulmonary Rehabilitation in Long-COVID-19 Patients with Persistent Breathlessness and Fatigue: The COVID-Rehab Study. Int. J. Environ. Res. Public Health. 2022;19:4133. doi: 10.3390/ijerph19074133.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19074133</ArticleId><ArticleId IdType="pmc">PMC8998214</ArticleId><ArticleId IdType="pubmed">35409815</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopp S., Moik F., Klok F.A., Gattinger D., Petrovic M., Vonbank K., Koczulla A.R., Ay C., Zwick R.H. Outpatient Pulmonary Rehabilitation in Patients with Long COVID Improves Exercise Capacity, Functional Status, Dyspnea, Fatigue, and Quality of Life. Respiration. 2022;101:593&#x2013;601. doi: 10.1159/000522118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000522118</ArticleId><ArticleId IdType="pmc">PMC9059007</ArticleId><ArticleId IdType="pubmed">35203084</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021;11:e048391. doi: 10.1136/bmjopen-2020-048391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Tziolos N.R., Ioannou P., Baliou S., Kofteridis D.P. Long COVID-19 Pathophysiology: What Do We Know So Far? Microorganisms. 2023;11:2458. doi: 10.3390/microorganisms11102458.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11102458</ArticleId><ArticleId IdType="pmc">PMC10609046</ArticleId><ArticleId IdType="pubmed">37894116</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazato Y., Morioka S., Tsuzuki S., Akashi M., Osanai Y., Tanaka K., Terada M., Suzuki M., Kutsuna S., Saito S., et al. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. Open Forum. Infect. Dis. 2020;7:ofaa507. doi: 10.1093/ofid/ofaa507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa507</ArticleId><ArticleId IdType="pmc">PMC7665672</ArticleId><ArticleId IdType="pubmed">33230486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.C., Hsu C.K., Yen M.Y., Lee P.I., Ko W.C., Hsueh P.R. Long COVID: An inevitable sequela of SARS-CoV-2 infection. J. Microbiol. Immunol. Infect. 2023;56:1&#x2013;9. doi: 10.1016/j.jmii.2022.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.10.003</ArticleId><ArticleId IdType="pmc">PMC9576029</ArticleId><ArticleId IdType="pubmed">36283919</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of Long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackey K., Ayers C.K., Kondo K.K., Saha S., Advani S.M., Young S., Spencer H., Rusek M., Anderson J., Veazie S., et al. Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths: A Systematic Review. Ann. Intern. Med. 2021;174:362&#x2013;373. doi: 10.7326/M20-6306.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-6306</ArticleId><ArticleId IdType="pmc">PMC7772883</ArticleId><ArticleId IdType="pubmed">33253040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopel J., Perisetti A., Roghani A., Aziz M., Gajendran M., Goyal H. Racial and Gender-Based Differences in COVID-19. Front. Public Health. 2020;8:418. doi: 10.3389/fpubh.2020.00418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.00418</ArticleId><ArticleId IdType="pmc">PMC7399042</ArticleId><ArticleId IdType="pubmed">32850607</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasanvand A. COVID-19 and the role of cytokines in this disease. Inflammopharmacology. 2022;30:789&#x2013;798. doi: 10.1007/s10787-022-00992-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00992-2</ArticleId><ArticleId IdType="pmc">PMC9064717</ArticleId><ArticleId IdType="pubmed">35505267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermejo-Martin J.F., Ortiz de Lejarazu R., Pumarola T., Rello J., Almansa R., Ramirez P., Martin-Loeches I., Varillas D., Gallegos M.C., Seron C., et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit. Care. 2009;13:R201. doi: 10.1186/cc8208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8208</ArticleId><ArticleId IdType="pmc">PMC2811892</ArticleId><ArticleId IdType="pubmed">20003352</ArticleId></ArticleIdList></Reference><Reference><Citation>Dastar S., Gharesouran J., Mortazavi D., Hosseinzadeh H., Kian S.J., Taheri M., Ghafouri-Fard S., Jamali E., Rezazadeh M. COVID-19 pandemic: Insights into genetic susceptibility to SARS-CoV-2 and host genes implications on virus spread, disease severity and outcomes. Hum. Antibodies. 2022;30:1&#x2013;14. doi: 10.3233/HAB-211506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/HAB-211506</ArticleId><ArticleId IdType="pubmed">34864654</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastassopoulou C., Gkizarioti Z., Patrinos G.P., Tsakris A. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Hum. Genomics. 2020;14:40. doi: 10.1186/s40246-020-00290-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40246-020-00290-4</ArticleId><ArticleId IdType="pmc">PMC7578581</ArticleId><ArticleId IdType="pubmed">33092637</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyerstedt S., Casaro E.B., Rangel &#xc9;.B. COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40:905&#x2013;919. doi: 10.1007/s10096-020-04138-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-04138-6</ArticleId><ArticleId IdType="pmc">PMC7778857</ArticleId><ArticleId IdType="pubmed">33389262</ArticleId></ArticleIdList></Reference><Reference><Citation>Scialo F., Daniele A., Amato F., Pastore L., Matera M.G., Cazzola M., Castaldo G., Bianco A. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung. 2020;198:867&#x2013;877. doi: 10.1007/s00408-020-00408-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-020-00408-4</ArticleId><ArticleId IdType="pmc">PMC7653219</ArticleId><ArticleId IdType="pubmed">33170317</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;hlendick B., Sch&#xf6;nfelder K., Breuckmann K., Elsner C., Babel N., Balfanz P., Dahl E., Dreher M., Fistera D., Herbstreit F., et al. ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19. Pharmacogenet Genom. 2021;31:165&#x2013;171. doi: 10.1097/FPC.0000000000000436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FPC.0000000000000436</ArticleId><ArticleId IdType="pmc">PMC8415730</ArticleId><ArticleId IdType="pubmed">34001841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir M.M., Mir R., Alghamdi M.A.A., Alsayed B.A., Wani J.I., Alharthi M.H., Al-Shahrani A.M. Strong Association of Angiotensin Converting Enzyme-2 Gene Insertion/Deletion Polymorphism with Susceptibility to SARS-CoV-2, Hypertension, Coronary Artery Disease and COVID-19 Disease Mortality. J. Pers. Med. 2021;11:1098. doi: 10.3390/jpm11111098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11111098</ArticleId><ArticleId IdType="pmc">PMC8621157</ArticleId><ArticleId IdType="pubmed">34834450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Sanz J., Jim&#xe9;nez D., Mart&#xed;nez-Campelo L., Cruz R., Vizcarra P., S&#xe1;nchez-Conde M., Ron R., Rodr&#xed;guez M., Herrera S., Moreno S., et al. Emerg Microbes Infect. Volume 10. Taylor &amp; Francis; New York, NY, USA: 2021. Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers; pp. 493&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7993370</ArticleId><ArticleId IdType="pubmed">33704002</ArticleId></ArticleIdList></Reference><Reference><Citation>Keikha M., Karbalaei M. Global distribution of ACE1 (rs4646994) and ACE2 (rs2285666) polymorphisms associated with COVID-19: A systematic review and meta-analysis. Microb. Pathog. 2022;172:105781. doi: 10.1016/j.micpath.2022.105781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2022.105781</ArticleId><ArticleId IdType="pmc">PMC9476369</ArticleId><ArticleId IdType="pubmed">36116608</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta K., Kaur G., Pathak T., Banerjee I. Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity. Gene. 2022;844:146790. doi: 10.1016/j.gene.2022.146790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2022.146790</ArticleId><ArticleId IdType="pmc">PMC9384365</ArticleId><ArticleId IdType="pubmed">35987511</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel G., Paola A.R., Nancy G., Fernando S.O., Beatriz A., Zulema R., Julieth A., Claudia C., Adriana R. Epigenetic mechanisms and host factors impact ACE2 gene expression: Implications in COVID-19 susceptibility. Infect. Genet. Evol. 2022;104:105357. doi: 10.1016/j.meegid.2022.105357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2022.105357</ArticleId><ArticleId IdType="pmc">PMC9420046</ArticleId><ArticleId IdType="pubmed">36038007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Arendt-Nielsen L., D&#xed;az-Gil G., G&#xf3;mez-Esquer F., Gil-Crujera A., G&#xf3;mez-S&#xe1;nchez S.M., Ambite-Quesada S., Palomar-Gallego M.A., Pellicer-Valero O.J., Giordano R. Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors. Genes. 2022;13:1935. doi: 10.3390/genes13111935.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13111935</ArticleId><ArticleId IdType="pmc">PMC9690177</ArticleId><ArticleId IdType="pubmed">36360172</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates A.D., Achuthan P., Akanni W., Allen J., Alvarez-Jarreta J., Amode M.R., Armean I.M., Azov A.G., Bennett R., Bhai J., et al. Ensembl 2020. Nucleic. Acids Res. 2020;48:D682&#x2013;D688. doi: 10.1093/nar/gkz966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz966</ArticleId><ArticleId IdType="pmc">PMC7145704</ArticleId><ArticleId IdType="pubmed">31691826</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C. Long COVID: Current definition. Infection. 2022;50:285&#x2013;286. doi: 10.1007/s15010-021-01696-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01696-5</ArticleId><ArticleId IdType="pmc">PMC8438555</ArticleId><ArticleId IdType="pubmed">34519974</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi N. Long COVID: How to define it and how to manage it. BMJ. 2020;370:m3489. doi: 10.1136/bmj.m3489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3489</ArticleId><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya A.A., Akbari A., Emami A., Lotfi M., Rostamihosseinkhani M., Nemati H., Barzegar Z., Kabiri M., Zeraatpisheh Z., Farjoud-Kouhanjani M., et al. Risk Factors Associated with Long COVID Syndrome: A Retrospective Study. Iran. J. Med. Sci. 2021;46:428&#x2013;436. doi: 10.30476/ijms.2021.92080.2326.</Citation><ArticleIdList><ArticleId IdType="doi">10.30476/ijms.2021.92080.2326</ArticleId><ArticleId IdType="pmc">PMC8611223</ArticleId><ArticleId IdType="pubmed">34840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Astin R., Banerjee A., Baker M.R., Dani M., Ford E., Hull J.H., Lim P.B., McNarry M., Morten K., O&#x2019;Sullivan O., et al. Long COVID: Mechanisms, risk factors and recovery. Exp. Physiol. 2023;108:12&#x2013;27. doi: 10.1113/EP090802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/EP090802</ArticleId><ArticleId IdType="pmc">PMC10103775</ArticleId><ArticleId IdType="pubmed">36412084</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirelli U., Taibi R., Chirumbolo S. Post COVID syndrome: A new challenge for medicine. Eur. Rev. Med. Pharmacol. Sci. 2021;25:4422&#x2013;4425. doi: 10.26355/eurrev_202106_26154.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202106_26154</ArticleId><ArticleId IdType="pubmed">34227079</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: An overview. Diabetes Metab. Syndr. 2021;15:869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera Martimbianco A.L., Pacheco R.L., Bagattini &#xc2;.M., Riera R. Frequency, signs and symptoms, and criteria adopted for Long COVID-19: A systematic review. Int. J. Clin. Pract. 2021;75:e14357. doi: 10.1111/ijcp.14357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14357</ArticleId><ArticleId IdType="pmc">PMC8236920</ArticleId><ArticleId IdType="pubmed">33977626</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya A.A., Akbari A., Emami A., Lotfi M., Rostamihosseinkhani M., Nemati H., Barzegar Z., Kabiri M., Zeraatpisheh Z., Farjoud-Kouhanjani M., et al. Long COVID syndrome-associated brain fog. J. Med. Virol. 2022;94:979&#x2013;984. doi: 10.1002/jmv.27404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27404</ArticleId><ArticleId IdType="pmc">PMC8662118</ArticleId><ArticleId IdType="pubmed">34672377</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar A.A.R., Yu T., Demko Z.O., Hu C., Tornheim J.A., Blair P.W., Thomas D.L., Manabe Y.C. Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. Front. Immunol. 2023;14:1147549. doi: 10.3389/fimmu.2023.1147549.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1147549</ArticleId><ArticleId IdType="pmc">PMC10176965</ArticleId><ArticleId IdType="pubmed">37187756</ArticleId></ArticleIdList></Reference><Reference><Citation>Heubner L., Petrick P.L., G&#xfc;ldner A., Bartels L., Ragaller M., Mirus M., Rand A., Tiebel O., Beyer-Westendorf J., R&#xf6;&#xdf;ler M., et al. Extreme obesity is a strong predictor for in-hospital mortality and the prevalence of long-COVID in severe COVID-19 patients with acute respiratory distress syndrome. Sci. Rep. 2022;12:18418. doi: 10.1038/s41598-022-22107-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-22107-1</ArticleId><ArticleId IdType="pmc">PMC9626466</ArticleId><ArticleId IdType="pubmed">36319681</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long COVID-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D., Savale L., Noel N., Meyrignac O., Colle R., Gasnier M., Corruble E., Beurnier A., Jutant E.M., Pham T., et al. Post-acute COVID-19 syndrome. Eur. Respir. Rev. 2022;31:601&#x2013;605. doi: 10.1183/16000617.0185-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0185-2021</ArticleId><ArticleId IdType="pmc">PMC8924706</ArticleId><ArticleId IdType="pubmed">35264409</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J.M., Rojas M., Salinas M.L., Rodr&#xed;guez Y., Roa G., Lozano M., Rodr&#xed;guez-Jim&#xe9;nez M., Montoya N., Zapata E., Monsalve D.M., et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun. Rev. 2021;20:102947. doi: 10.1016/j.autrev.2021.102947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102947</ArticleId><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagadinou M., Kostopoulou E., Karatza A., Marangos M., Gkentzi D. The prolonged effects of COVID-19. A new &#x201c;threat&#x201d;? Eur. Rev. Med. Pharmacol. Sci. 2021;25:4611&#x2013;4615. doi: 10.26355/eurrev_202107_26253.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202107_26253</ArticleId><ArticleId IdType="pubmed">34286502</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton R., Ansdell P., Hume E., Maden-Wilkinson T., Ryan D., Tuttiett E., Faghy M. COVID-19 and the long-term cardio-respiratory and metabolic health complications. Rev. Cardiovasc. Med. 2022;23:53. doi: 10.31083/j.rcm2302053.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm2302053</ArticleId><ArticleId IdType="pubmed">35229544</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovarik J.J., Bileck A., Hagn G., Meier-Menches S.M., Frey T., Kaempf A., Hollenstein M., Shoumariyeh T., Skos L., Reiter B., et al. A multi-omics based anti-inflammatory immune signature characterizes Long COVID-19 syndrome. iScience. 2023;26:105717. doi: 10.1016/j.isci.2022.105717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105717</ArticleId><ArticleId IdType="pmc">PMC9719844</ArticleId><ArticleId IdType="pubmed">36507225</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan-Blitz L.T., Akbari O., Kojima N., Saavedra E., Chellamuthu P., Denny N., MacMullan M.A., Hess V., Shacreaw M., Brobeck M., et al. Unique immune and inflammatory cytokine profiles may define Long COVID syndrome. Clin. Exp. Med. 2023;23:2925&#x2013;2930. doi: 10.1007/s10238-023-01065-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-023-01065-6</ArticleId><ArticleId IdType="pmc">PMC10105906</ArticleId><ArticleId IdType="pubmed">37061998</ArticleId></ArticleIdList></Reference><Reference><Citation>Saengsiwaritt W., Jittikoon J., Chaikledkaew U., Udomsinprasert W. Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: A systematic review with meta-analysis. Rev. Med. Virol. 2022;32:e2323. doi: 10.1002/rmv.2323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2323</ArticleId><ArticleId IdType="pubmed">34997794</ArticleId></ArticleIdList></Reference><Reference><Citation>Atiku S.M., Kasozi D., Campbell K. Single Nucleotide Variants (SNVs) of Angiotensin-Converting Enzymes (ACE1 and ACE2): A Plausible Explanation for the Global Variation in COVID-19 Prevalence. J. Renin. Angiotensin Aldosterone Syst. 2023;2023:9668008. doi: 10.1155/2023/9668008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/9668008</ArticleId><ArticleId IdType="pmc">PMC10085651</ArticleId><ArticleId IdType="pubmed">37051471</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F., Zhang Y., Li X., Li W., Liu X., Xue X. The Impact of ACE2 Polymorphisms on COVID-19 Disease: Susceptibility, Severity, and Therapy. Front. Cell Infect. Microbiol. 2021;11:753721. doi: 10.3389/fcimb.2021.753721.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.753721</ArticleId><ArticleId IdType="pmc">PMC8569405</ArticleId><ArticleId IdType="pubmed">34746028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren W., Zhu Y., Lan J., Chen H., Wang Y., Shi H., Feng F., Chen D.Y., Close B., Zhao X., et al. Susceptibilities of Human ACE2 Genetic Variants in Coronavirus Infection. J. Virol. 2022;96:e0149221. doi: 10.1128/JVI.01492-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01492-21</ArticleId><ArticleId IdType="pmc">PMC8754202</ArticleId><ArticleId IdType="pubmed">34668773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakhshandeh B., Sorboni S.G., Javanmard A.R., Mottaghi S.S., Mehrabi M.R., Sorouri F., Abbasi A., Jahanafrooz Z. Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infect. Genet Evol. 2021;90:104773. doi: 10.1016/j.meegid.2021.104773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2021.104773</ArticleId><ArticleId IdType="pmc">PMC7886638</ArticleId><ArticleId IdType="pubmed">33607284</ArticleId></ArticleIdList></Reference><Reference><Citation>Taher I., Almaeen A., Ghazy A., Abu-Farha M., Mohamed Channanath A., Elsa John S., Hebbar P., Arefanian H., Abubaker J., Al-Mulla F., et al. Relevance between COVID-19 and host genetics of immune response. Saudi. J. Biol. Sci. 2021;28:6645&#x2013;6652. doi: 10.1016/j.sjbs.2021.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sjbs.2021.07.037</ArticleId><ArticleId IdType="pmc">PMC8285220</ArticleId><ArticleId IdType="pubmed">34305429</ArticleId></ArticleIdList></Reference><Reference><Citation>Adli A., Rahimi M., Khodaie R., Hashemzaei N., Hosseini S.M. Role of genetic variants and host polymorphisms on COVID-19: From viral entrance mechanisms to immunological reactions. J. Med. Virol. 2022;94:1846&#x2013;1865. doi: 10.1002/jmv.27615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27615</ArticleId><ArticleId IdType="pmc">PMC9015257</ArticleId><ArticleId IdType="pubmed">35076118</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Wang Y., Liu Y., Zhang Z., Zhai Y., Dai Y., Wu Z., Nie X., Du L. Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: A systematic review. Eur. J. Med. Res. 2022;27:26. doi: 10.1186/s40001-022-00647-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-022-00647-6</ArticleId><ArticleId IdType="pmc">PMC8861605</ArticleId><ArticleId IdType="pubmed">35193695</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain M.S., Tonmoy M.I.Q., Fariha A., Islam M.S., Roy A.S., Islam M.N., Kar K., Alam M.R., Rahaman M.M. Prediction of the Effects of Variants and Differential Expression of Key Host Genes ACE2, TMPRSS2, and FURIN in SARS-CoV-2 Pathogenesis: An In Silico Approach. Bioinform. Biol. Insights. 2021;15:11779322211054684. doi: 10.1177/11779322211054684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11779322211054684</ArticleId><ArticleId IdType="pmc">PMC8554545</ArticleId><ArticleId IdType="pubmed">34720581</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabater Molina M., Nicol&#xe1;s Rocamora E., Bendicho A.I., V&#xe1;zquez E.G., Zorio E., Rodriguez F.D., Gil Ortu&#xf1;o C., Rodr&#xed;guez A.I., S&#xe1;nchez-L&#xf3;pez A.J., Jara Rubio R., et al. Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease. PLoS ONE. 2022;17:e0263140. doi: 10.1371/journal.pone.0263140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0263140</ArticleId><ArticleId IdType="pmc">PMC8815985</ArticleId><ArticleId IdType="pubmed">35120165</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>